NCT01529749View on ClinicalTrials.gov

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2012

Study Completion Date

February 29, 2016

Conditions
HIV-1 Infection
Interventions
DRUG

EFV/FTC/TDF + Losartan

EFV/FTC/TDF --\> oral, 600/200/245 mg, od Losartan --\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.

DRUG

EFV/FTC/TDF

600/200/245 mg, od, oral

DRUG

FTC/TDF + MK-0518

FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral

DRUG

FTC/TDF+MK-0518+Losartan

FTC/TDF --\> 200/245 mg, oral MK-0518 --\> 400 mg, oral Losartan --\> -\> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.

Trial Locations (1)

08036

Hospital Clinic, Barcelona

All Listed Sponsors
lead

Felipe Garcia

OTHER

NCT01529749 - Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated | Biotech Hunter | Biotech Hunter